Qiagen: New Launches Signal A Turnaround

Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum.

Qiagen N.V. ( QGEN ) has new launches , which I believe might drive a bullish reversal. This is after its stock price dipped by around -10.83% YTD. In my opinion, I believe this is an ideal entry point, as new